Literature DB >> 32739317

Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria.

Won Hee Lee1, Hwa Kyung Byun1, Jin Sub Choi2, Gi Hong Choi2, Dai Hoon Han2, Dong Jin Joo2, Do Young Kim3, Kwang-Hyub Han3, Jinsil Seong4.   

Abstract

BACKGROUND AND
PURPOSE: Liver-directed combined radiotherapy (LDCRT) can provide substantial tumor control, which may be an effective bridge to curative surgery for selected patients. We aimed to investigate the outcomes of LDCRT for locally advanced hepatocellular carcinoma (LAHCC) beyond the Milan criteria.
MATERIALS AND METHODS: We identified 1078 patients diagnosed with LAHCC who received LDCRT and compared the outcomes based on no surgery, conversion to surgical resection, and liver transplantation (LT). Predictive factors for conversion to curative surgery were identified using logistic regression analysis.
RESULTS: The most frequently used LDCRT strategies were concurrent chemoradiation (CCRT) (497 patients, 46.1%) and transarterial chemoembolization (TACE) plus radiotherapy (251 patients 23.3%). After LDCRT, 96 (8.9%) and 42 patients (3.9%) received surgical resection and LT, respectively. After a median follow-up of 14.4 months, the 5-year overall survival (OS) rate was 16.5% for all patients. Conversion to curative surgery group had higher 5-year OS (surgical resection vs. LT vs. no surgery: 58.1% vs. 54.3% vs. 10.2%, p < 0.001). Patients aged < 60 years with a single tumor, no treatment history, pre-treatment Child class A, lower pre-treatment tumor marker levels, and radiologic complete or partial response (all p < 0.050) had a higher chance of conversion to surgery.
CONCLUSION: LDCRT could convert tumors to within the Milan criteria as a bridge to curative surgery, and improved long-term survival for the selected patients. Clinicians should consider LDCRT followed by curative surgery for young patients who are treatment-naïve and have good liver function with favorable tumor characteristics showing radiologic response to LDCRT.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Hepatocellular carcinoma; Liver transplantation; Multi-modality treatment; Surgery; Therapeutic chemoembolization

Mesh:

Year:  2020        PMID: 32739317     DOI: 10.1016/j.radonc.2020.07.046

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Biomarkers for Locally Advanced Hepatocellular Carcinoma Patients Treated with Liver-Directed Combined Radiotherapy.

Authors:  Seung Yeun Chung; Kyoung-Jin Kim; Jinsil Seong
Journal:  Liver Cancer       Date:  2022-01-24       Impact factor: 12.430

Review 2.  Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review.

Authors:  Zhewen Wei; Jianjun Zhao; Xinyu Bi; Yefan Zhang; Jianguo Zhou; Zhiyu Li; Zhen Huang; Hong Zhao; Jianqiang Cai
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

3.  Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Authors:  Jina Kim; Hwa Kyung Byun; Tae Hyung Kim; Sun Il Kim; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Jinsil Seong
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

4.  Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study.

Authors:  Hui-Zhou Li; Jie Tan; Tian Tang; Tian-Zhi An; Jun-Xiang Li; Yu-Dong Xiao
Journal:  J Hepatocell Carcinoma       Date:  2021-11-01

5.  HDR Brachytherapy and SBRT as Bridging Therapy to Liver Transplantation in HCC Patients: A Single-Center Experience.

Authors:  Franziska Walter; Frederik Fuchs; Sabine Gerum; Maya C Rottler; Robert Erdelkamp; Jens Neumann; Lukas Nierer; Markus Guba; Enrico N De Toni; Max Seidensticker; Jens Ricke; Claus Belka; Stefanie Corradini
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.